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The expert panel of hepatobiliary surgeons has presented an
expansive and comprehensively thought out review on a number
of key issues that continue to challenge the oncology community,
especially regarding which of the various local or regional thera-
pies are optimal and their best timing in patients with colorectal
cancer and liver metastasis.1 The authors have expertly broken
these challenges into four key areas: approaches to bilateral color-
ectal liver metastasis; approaches to synchronous presentations of
colorectal cancer and liver metastasis; intra-arterial therapies, and
ablation strategies that include the use of radiofrequency and
microwave technology and external beam radiotherapy.1 These
topics are reviewed to varying extents and key consensus state-
ments given at the end of each section to provide further guidance
in the management of colorectal liver metastasis.
The optimal approach and timing in the surgical therapy of
patients with bilateral colorectal liver metastasis remain challeng-
ing because of the substantial heterogeneity among patients in
this group. Clear consensus indicates that the ability to remove
all metastatic deposits, leaving an adequate liver remnant, is key
to the underlying definition of resectability.2 Variables that con-
found this definition include the presence of significant under-
lying comorbidity in the patient, the timing of the patient’s
referral based on the extent of chemotherapy that has been
administered, the underlying bias of the referring medical
oncologist and, lastly, the underlying desire of the patient, pre-
dominantly based on his or her overall goals and understanding
of the overall outlook for survival.
One-stage hepatectomy optimizing the parenchyma-sparing
techniques of either resection or ablation is an evolving technique
that can be used in patients with bilateral colorectal metastasis for
multiple reasons; these include the technique’s facility to allow
the avoidance of a second operative procedure and to ensure that
any interruption of chemotherapy is minimized. As the authors
have highlighted, the incidence of recurrence in patients with
bilateral colorectal metastasis is high, even when complete resec-
tion has been achieved.1 This high level of recurrence is strongly
acknowledged by the medical oncology community and thus
reducing the overall duration of interruption of chemotherapy
remains a goal. Hypothetically, a one-stage operation might ben-
eficially address local liver-specific progression and even overall
progression. Any continued interruption of therapy should not
exceed 12 weeks, which should include a 4-week period prior to
hepatectomy and a 6–8-week recovery period after hepatectomy.
Based on these criteria, one-stage hepatectomy aimed at achiev-
ing optimal lesion control through the complete resection and/or
ablation of all disease should and can be considered. The authors
suggest a very conservative ablation diameter of  1 cm, a stand-
ard that has been disproven in a number of key ablation articles.1
Other experienced surgeons utilizing high-quality intraoperative
ultrasound have shown that lesions measuring < 3 cm in size can
be treated successfully with up-to-date ablation modalities and
outcomes similar to those obtained in wedge resection or sub-
segmental resection can be achieved.3–6 Thus, consideration
should be given to methods of optimizing a one-stage technique
using resection or ablation alone or a combination of these under
the appropriate circumstances.
Appropriately, and with initial enthusiasm, the authors
mention the continued evaluation of the use of intra-arterial
therapies to downsize metastasis.1 A large amount of safety data
derived from patients who have undergone hepatectomy follow-
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or a combination of these is available from a number of high-
volume institutions.7–9 Hepatectomy performed at least 4–6
months after radioembolization or drug-eluting bead therapy
appears to be safe. Similarly, hepatectomy after prior intra-arterial
therapy appears to be safe.9 Thus, patients in whom disease has
been downsized by such intra-arterial therapies should undergo
evaluation for surgical treatment of all known disease.
The optimal approach to synchronous presentations of color-
ectal and liver metastases has been well established and continues
to evolve through the three different surgical strategies outlined in
the consensus paper.1 The respective benefits and efficacies of the
‘simultaneous’, ‘colorectal first’ and ‘liver first’ approaches have
each been demonstrated in the appropriate setting based on indi-
vidual patient characteristics. The advent of minimally invasive
hepatectomy contributes further to the consideration of timing
and extent of resection.10–13 Recent reports from a number of large
institutions have demonstrated the possible advantages to be
derived from the use of laparoscopic hepatectomy in patients with
colorectal liver metastasis, predominantly in the reduction of
adverse events and overall length of stay, as well as in overall
improvements in quality of life.14
The authors have appropriately reviewed the use of hepatic–
arterial infusion (HAI) therapy and clearly state that surgeon
technique and volume are key components to the delivery
of successful HAI therapy.1 It should be emphasized that an
additional key to the success of HAI therapy is the medical
oncologist.15,16 The complexity of patient management and the
apparently limited overall benefit to be derived from this therapy
outwith the context of programmes with extensive experience
have raised questions on its sustainability.17 Trial-based evidence
of patient benefit is required prior to wider acceptance of this
therapy and specialty expertise will remain mandatory for its
successful implementation.
The consensus document addresses chemoembolization by
combining conventional transcatheter arterial chemoemboliza-
tion (TACE) and newer approaches using drug-eluting beads.1 It
should be noted that these are quite different therapies; they use
different types of chemotherapy and catheter, and involve different
arterial flow endpoints.18 Therapeutic TACE typically entails the
delivery of chemotherapywith embolic flow stasis in the segmental
artery of the treated lesion, whereas therapy with drug-eluting
beads does not seek to induce stasis because in this context stasis
tends to increase morbidity without increasing overall efficacy.18,19
A further question regarding arterial embolization therapies
refers to their timing in the sequence of multidisciplinary therapy
for advanced colorectal liver metastases. Should intra-arterial
therapy be considered after systemic chemotherapy failure or
earlier in the sequence for an enhanced response? Is there even a
role for arterial embolization in high-risk resectable disease in
terms of improving recurrence-free survival? The consensus
paper is not able to provide clear guidelines in this respect
because data are not yet available and the field is rapidly evolv-
ing. First-line trials in unresectable liver only/liver-dominant
colorectal liver metastasis with yttrium-90 (http://clinicaltrials.
gov/ct2/show/NCT00724503) and drug-eluting bead therapy
(http://clinicaltrials.gov/ct2/show/NCT00932438), and a trial of
yttrium-90 as a second-line therapy (http://clinicaltrials.gov/ct2/
show/NCT01483027) are currently enrolling. Progress in this
area is therefore anticipated, but the issues involved will remain
topics of major debate.
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